INCRUSE ELLIPTA (umeclidinium) Patient Assistance Program
Don’t let the high cost of brand specialty COPD inhalers disrupt your treatment. We help eligible patients access Anoro Ellipta (umeclidinium/vilanterol) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Incruse Ellipta (umeclidinium) is FDA-approved for the long-term, once-daily maintenance treatment of airflow obstruction in adults with COPD, including chronic bronchitis and emphysema. It is a long-acting muscarinic antagonist (LAMA) delivered via the Ellipta dry-powder inhaler.
- Without assistance, the average retail price runs approximately $370–$470 per Ellipta inhaler (30 doses, one month).
- Through AffordMyPrescriptions, qualifying patients can access Incruse Ellipta for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic version of Incruse Ellipta available in the U.S. as of 2026. Other LAMAs are FDA-approved (tiotropium/Spiriva, glycopyrrolate, aclidinium, revefenacin), some with generic or lower-cost options.
What Is Incruse Ellipta Prescription Assistance Program?
The Incruse Ellipta Prescription Assistance Program is a manufacturer-sponsored initiative that provides Incruse at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for COPD patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, prescriber coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your breathing, not paperwork.
Pharmacy Price Comparison
- Without assistance, Incruse Ellipta costs roughly $370–$470 per inhaler. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$450.00 | Save ~$380/inhaler |
| CVS Pharmacy | ~$470.00 | Save ~$400/inhaler |
| Walmart | ~$390.00 | Save ~$320/inhaler |
| Costco | ~$375.00 | Save ~$305/inhaler |
| Kroger | ~$385.00 | Save ~$315/inhaler |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Incruse Ellipta Prescription Program?
The Patient Assistance Program is free to apply for and provides Incruse Ellipta at no medication cost if approved. But the process involves detailed applications, prescriber coordination, prior-authorization documentation, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Incruse Ellipta:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $370–$470 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Incruse Ellipta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Incruse Ellipta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Incruse Ellipta:
Incruse Ellipta (umeclidinium) is a once-daily long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of airflow obstruction in adults with COPD. It is delivered via the Ellipta dry-powder inhaler. Incruse is a controller — not a rescue inhaler. Patients with sudden COPD exacerbations should still use a separate short-acting bronchodilator.
How Incruse Ellipta Works:
Incruse Ellipta treats COPD by blocking cholinergic signals that cause airway muscles to contract and narrow. Its active ingredient, umeclidinium, is a long-acting muscarinic antagonist (LAMA) that selectively targets receptors on the smooth muscle of the airways. By preventing these constriction signals, the medication relaxes the airways and provides improved airflow for a full 24 hours with a single dose.
Form and use:
This medication is administered as one inhalation once daily at the same time each day using a dry-powder inhaler. Each device provides a 30-day supply, and patients should rinse their mouth after use to minimize dry mouth. It is important to note that Incruse is a maintenance controller for COPD only—not for asthma—and it should never be used as a rescue inhaler for sudden symptoms.
Generic availability:
As of 2026, there is no FDA-approved generic version of Incruse Ellipta available in the United States. However, other LAMA options exist, such as Spiriva HandiHaler, which now has a generic version available. Patients requiring additional symptom control may also consider LAMA/LABA combinations like Anoro Ellipta or other branded alternatives such as Stiolto Respimat or Bevespi Aerosphere.
Warnings:
Incruse Ellipta is not intended for the treatment of asthma or acute COPD exacerbations. Significant warnings include the risk of paradoxical bronchospasm, worsening of narrow-angle glaucoma, and increased urinary retention, particularly in men with BPH. Users should promptly contact their healthcare provider if they experience sudden breathing problems, eye pain, vision changes, or difficulty urinating.
FAQ (Frequently Asked Questions)
How Much Does Incruse Ellipta Cost Without Insurance?
The average retail price runs approximately $370–$470 per Ellipta inhaler. Through AffordMyPrescriptions, qualifying patients receive Incruse at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Incruse Different From Other LAMAs?
Incruse Ellipta (umeclidinium) is a once-daily LAMA delivered via the Ellipta dry-powder inhaler. Other once-daily LAMAs include tiotropium (Spiriva, with a generic now available), revefenacin (Yupelri, nebulizer-delivered). Twice-daily LAMAs include aclidinium (Tudorza). Whether one is a better fit depends on your inhaler technique preference, formulary, and tolerability
Is This A Rescue Inhaler?
No. Incruse Ellipta is a controller (maintenance) inhaler — taken once daily on a regular schedule. It is not for the acute treatment of bronchospasm or sudden worsening of breathing. You should still have a separate short-acting rescue inhaler (typically albuterol) for sudden symptoms.
Can I Use Incruse For Asthma?
No. Incruse Ellipta is approved only for COPD, not asthma. LAMA monotherapy is generally not recommended for asthma; in asthma, LAMAs (when used) should be added to ICS-containing regimens. Your prescriber will recommend the right inhaler for your condition.
Are There Cheaper Alternatives I Should Know About?
Yes. Tiotropium (Spiriva HandiHaler) now has a generic available. Some formularies prefer specific LAMAs based on contracts. We mention this directly because depending on your insurance, a different LAMA may have lower out-of-pocket cost than brand Incruse. Discuss with your prescriber.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — generic tiotropium, the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the COPD Foundation, American Lung Association, PAN Foundation, or HealthWell Foundation, or asking your prescriber whether a different LAMA on a more accessible cost path would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Incruse Ellipta, our team may be able to help you access assistance programs designed to make brand specialty COPD inhalers affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.